Thomas Leggett Net Worth

The estimated Net Worth of Thomas Leggett is at least $2.05 Million dollars as of 8 January 2021. Mr. Leggett owns over 3,000 units of Black Diamond Therapeutics Inc stock worth over $18,390 and over the last 5 years he sold BDTX stock worth over $0. In addition, he makes $2,026,620 as Chief Financial Officer at Black Diamond Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Leggett BDTX stock SEC Form 4 insiders trading

Thomas has made over 5 trades of the Black Diamond Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of BDTX stock worth $32,580 on 8 January 2021.

The largest trade he's ever made was exercising 3,000 units of Black Diamond Therapeutics Inc stock on 8 January 2021 worth over $32,580. On average, Thomas trades about 1,875 units every 15 days since 2020. As of 8 January 2021 he still owns at least 3,000 units of Black Diamond Therapeutics Inc stock.

You can see the complete history of Mr. Leggett stock trades at the bottom of the page.

Thomas Leggett biography

Thomas Leggett serves as Chief Financial Officer of the Company. Prior to joining us, from January 2017 to August 2019, Mr. Leggett served as Senior Vice President of Finance and Chief Financial Officer at Axcella Health Inc., a biotechnology company. Prior to joining Axcella, Mr. Leggett served as the Treasurer and Head of Business Development Finance at Purdue Pharma L.P., a pharmaceutical company, from May 2016 to December 2017. From November 2009 to April 2016, Mr. Leggett was an Executive Director at UBS Securities LLC, an investment bank, in the Global Healthcare Group with a primary focus in the biopharmaceutical sector. Mr. Leggett holds an M.B.A. in finance from The Wharton School at the University of Pennsylvania and a B.A. in Economics from Columbia University.

What is the salary of Thomas Leggett?

As the Chief Financial Officer of Black Diamond Therapeutics Inc, the total compensation of Thomas Leggett at Black Diamond Therapeutics Inc is $2,026,620. There are 1 executives at Black Diamond Therapeutics Inc getting paid more, with David Epstein having the highest compensation of $3,346,080.

How old is Thomas Leggett?

Thomas Leggett is 43, he's been the Chief Financial Officer of Black Diamond Therapeutics Inc since 2019. There are 16 older and 1 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.

What's Thomas Leggett's mailing address?

Thomas's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.

Insiders trading at Black Diamond Therapeutics Inc

Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah, and Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.

What does Black Diamond Therapeutics Inc do?

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.

Complete history of Mr. Leggett stock trades at Black Diamond Therapeutics Inc and Stoke Therapeutics

Black Diamond Therapeutics Inc executives and stock owners

Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Epstein,
  President, Chief Executive Officer, Director
• Thomas Leggett,
  Chief Financial Officer
• Christopher Roberts,
  Chief Scientific Officer
• Dr. David M. Epstein Ph.D.,
  Co-Founder, Pres, CEO & Director
• Brent Hatzis-Schoch Esq., J.D.,
  COO & Gen. Counsel
• Samarth Kulkarni,
  Independent Director
• Dr. Rachel Wallach Humphrey M.D., Ph.D.,
  Advisor
• Garry Menzel,
  Independent Director
• Rajeev Shah,
  Independent Director
• Ali Behbahani,
  Independent Director
• Alexander Mayweg,
  Director
• Bradley Bolzon,
  Director
• Fang Ni,
  Chief Business Officer
• Rachel Humphrey,
  Chief Medical Officer
• Karsten Witt,
  Senior Vice President - Non-Clinical Development
• Elizabeth Buck,
  Executive Vice President - Discovery and Translational Services
• Brent Hatzis-Schoch,
  Chief Operating Officer, General Counsel
• Robert Ingram,
  Independent Chairman of the Board
• Tai-An Lin Ph.D.,
  VP & Head of Biology
• Dr. Karsten Witt M.D.,
  Sr. VP of Clinical Devel. & Interim Chief Medical Officer
• Dr. Christopher D. Roberts Ph.D.,
  Advisor
• Erika Jones,
  VP of Fin., Corp. Controller & Principal Accounting Officer
• Dr. Fang Ni Pharm.D.,
  CFO, Principal Financial Officer and Chief Bus. Officer
• Dr. Elizabeth Buck Ph.D.,
  Co-Founder & Chief Scientific Officer
• James E Deerfield Mgmt L.P....,
  
• Sergey Yurasov,
  CHIEF MEDICAL OFFICER
• Shannon Campbell,
  
• Prakash Raman,
  
• Venture Capital Vi, L.P.Ver...,
  
• Biomedical Innovation Maste...,
  10% owner
• Venture Capital Vi, L.P.Ver...,
  
• Erika Jones,
  SEE REMARKS
• Wendy L Dixon,
  
• Growth N Vbb Biotech Ag Bio...,
  
• Kapil Dhingra,
  
• Capital Management, L.P.Ra ...,
  
• Mark A. Velleca,
  PRESIDENT & CEO